Susquehanna International Group
DNLI icon

Susquehanna International Group’s Denali Therapeutics DNLI Stock Holding History

Susquehanna International Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$969K Buy
50,475
+15,707
+45% +$313K ﹤0.01% 7967
2025
Q4 		$574K Sell
34,768
-6,218
-15% -$105K ﹤0.01% 8461
2025
Q3 		$595K Sell
40,986
-120,150
-75% -$1.73M ﹤0.01% 8571
2025
Q2 		$2.25M Sell
161,136
-6,061
-4% -$85.3K ﹤0.01% 5542
2025
Q1 		$2.27M Buy
167,197
+95,957
+135% +$1.84M ﹤0.01% 5237
2024
Q4 		$1.45M Buy
71,240
+21,070
+42% +$539K ﹤0.01% 6025
2024
Q3 		$1.46M Sell
50,170
-10,228
-17% -$254K ﹤0.01% 5973
2024
Q2 		$1.4M Sell
60,398
-44,242
-42% -$849K ﹤0.01% 5819
2024
Q1 		$2.15M Buy
104,640
+43,726
+72% +$822K ﹤0.01% 5168
2023
Q4 		$1.31M Sell
60,914
-32,889
-35% -$651K ﹤0.01% 6327
2023
Q3 		$1.94M Sell
93,803
-23,789
-20% -$603K ﹤0.01% 5197
2023
Q2 		$3.47M Sell
117,592
-222,972
-65% -$6.27M ﹤0.01% 4129
2023
Q1 		$7.85M Buy
340,564
+317,311
+1,365% +$8.73M ﹤0.01% 2802
2022
Q4 		$647K Sell
23,253
-73,374
-76% -$2.18M ﹤0.01% 7207
2022
Q3 		$2.97M Buy
96,627
+86,101
+818% +$2.8M ﹤0.01% 4118
2022
Q2 		$310K Sell
10,526
-75,192
-88% -$1.97M ﹤0.01% 9478
2022
Q1 		$2.76M Sell
85,718
-33,177
-28% -$1.14M ﹤0.01% 4780
2021
Q4 		$5.3M Buy
118,895
+66,798
+128% +$3.16M ﹤0.01% 3637
2021
Q3 		$2.63M Buy
52,097
+32,872
+171% +$1.85M ﹤0.01% 5241
2021
Q2 		$1.51M Buy
19,225
+4,101
+27% +$254K ﹤0.01% 6625
2021
Q1 		$864K Sell
15,124
-9,996
-40% -$669K ﹤0.01% 8106
2020
Q4 		$2.1M Buy
25,120
+8,737
+53% +$528K ﹤0.01% 4988
2020
Q3 		$587K Buy
16,383
+3,700
+29% +$111K ﹤0.01% 7336
2020
Q2 		$307K Sell
12,683
-27,441
-68% -$645K ﹤0.01% 8322
2020
Q1 		$703K Buy
+40,124
New +$837K ﹤0.01% 6181
2019
Q4 		– Sell
-59,852
Closed -$996K – 9862
2019
Q3 		$917K Buy
59,852
+21,927
+58% +$419K ﹤0.01% 5859
2019
Q2 		$787K Buy
+37,925
New +$850K ﹤0.01% 6233

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's DNLI Position: Q1 2026 in Review

Susquehanna International Group increased its Denali Therapeutics (DNLI) stake by 45% in Q1 2026, buying an estimated $313K and bringing the position to 50,475 shares worth $969K. The position accounts for ﹤0.01% of the portfolio, ranked #7967.

Susquehanna International Group first reported a position in DNLI in Q2 2019 and has held it in 27 quarters since. The position peaked at $7.85M in Q1 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Susquehanna International Group held 50,475 shares of Denali Therapeutics worth $969K as of Q1 2026.
  • Susquehanna International Group bought 15,707 Denali Therapeutics shares in Q1 2026, an estimated $313K.
  • Denali Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7967 holding.
  • Susquehanna International Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Denali Therapeutics position peaked at $7.85M in Q1 2023.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.